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What every intensivist should know about the 
management of peritonitis in the intensive care unit
COMMENTARY
Introduction
Complicated intra-abdominal infections (cIAI) are among the more 
challenging infections in the intensive care unit, not only because they are 
typically associated with more severe organ dysfunction(1) but also because the 
need for an intervention is more important than in other infections.(2) In recent 
years, a number of new challenges have been added, further complicating the 
decision-making process for these patients, who are often vulnerable. In this 
document, we will focus on the key elements in the management of these 
patients and review the latest evidence.
Multidrug resistance is a pressing issue, also in peritonitis…
Multidrug resistance (MDR) is increasing worldwide, and there are 
important geographical differences for various pathogens.(3) Whereas most of 
the data on MDR focus on respiratory tract infections, it is a similar issue in 
cIAI, most notably in patients with hospital acquired infections.(4,5)
There are a number of reasons why MDR is a highly relevant topic in 
cIAI. First, cIAI are typically polymicrobial infections, and resistance may be 
present in both Gram-negative (most notably Enterobacteraceae) and Gram-
positive pathogens, such as Enterococcus faecium, in the same patient. Second, 
the duration of antibiotic therapy is often longer and driven by a lack of a 
source of control, requiring multiple surgical interventions.(6,7) This is most 
explicitly reflected in patients with tertiary peritonitis, for whom often-resistant 
pathogens that are difficult to eradicate cause persistent inflammation of the 
peritoneal cavity.(8)
Multidrug resistance is particularly problematic in hospitalized patients and 
in patients who have been exposed to antibiotics prior to or for the therapy of 
the current cIAI.(9,10) However, MDR is also increasing in community-acquired 
infections, with extended-spectrum beta-lactamase (ESBL)-producing bacteria 
being the most globally widespread problem, although there is important 
regional variation in its prevalence.(11,12) In nosocomial infections,(4,9,13) 
both Gram-positive and Gram-negative pathogens that have MDR may be 
encountered, and these include methicillin-resistant Staphylococcus aureus 
(MRSA), vancomycin-resistant enterococci (VRE) and ESBL-producing 
Enterobacteraceae but also carbapenem-resistant Enterobacteraceae (CRE), MDR 
Pseudomonas aeruginosa and Acinetobacter spp., which also have important 
geographical variations.
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…, which makes rational antibiotic use even more 
important today
The threat of MDR inevitably poses problems in the 
empirical therapy of cIAI, and the use of multiple and 
broad-spectrum antibiotics is a logical consequence that 
fuels the vicious cycle.(3)
Empirical antibiotic therapy should therefore be based 
on knowledge of the local epidemiology, and the antibiotic 
with the least broad spectrum is preferred.(14) Patients at 
the highest risk of MDR infection include those who have 
been treated with antibiotics and patients who have been 
residing in the hospital in the previous weeks. Because of 
the same problem of MDR, intraoperative cultures are 
mandatory in nosocomial infections(15) and antibiotic 
de-escalation can be safely performed when cultures are 
available.(6)
However, the first question should be whether the 
patient really needs antibiotics. There are a number of 
conditions often encountered in the intensive care unit 
(ICU) that do not need antibiotic therapy beyond the 
prophylactic antibiotics related to a surgical intervention 
(Table 1).(14) Particularly relevant to the ICU are 
postoperative patients who had abdominal trauma from 
intestinal ischemia that required intervention. Another 
source of concern in patients who have been treated for 
abdominal infections are abdominal drains. Cultures 
from abdominal drains should be carefully interpreted, 
as biofilms and colonization occur very frequently. 
As it is often difficult to discriminate infection from 
colonization, routine cultures of abdominal drains are 
not recommended. Although these can identify recurrent 
infections or an inadequate source control, their actual 
value in the management of abdominal infections has not 
been demonstrated.
Pharmacokinetic properties of antibiotics have been 
insufficiently studied in complicated intra-abdominal 
infections patients
There is ample evidence suggesting that the 
pharmacokinetics of antibiotics in critically ill patients is 
different from that in healthy volunteers or patients in the 
general ward.(16) This is mainly driven by increases in the 
volume of distribution and changes in the elimination of 
the drug. Most of the antibiotics used in the treatment 
of peritonitis are beta-lactam antibiotics, which are 
eliminated from the circulation by the kidneys. Therefore, 
their elimination can be enhanced (e.g., in patients with 
augmented renal clearance) or reduced (e.g., in patients 
with acute kidney injury (AKI)).
These pharmacokinetic (PK) changes are enhanced in 
peritonitis by a number of additional challenges.(17) First, 
these patients often require surgery, in which blood loss 
and volume replacement may further reduce the antibiotic 
concentrations. Also, bleeding from the surgical site 
may persist into the postoperative period and affect the 
PK status. Moreover, loss of fluids, those that are often 
protein-rich, may further lead to losses of antibiotics 
via the abdominal drains. In patients treated with open 
abdomen therapy in the early postoperative phase, active 
negative pressure may induce significant fluid losses via 
the abdominal cavity.
As a result, antibiotic concentrations in the peritoneal 
fluid at the site of infection are highly unpredictable, and 
this has been poorly investigated.
New antibiotic agents are available for 
multidrug-resistant pathogens but should be used 
selectively
Several new antibiotics that include MDR pathogens 
in their spectrum have been introduced recently, and most 
of them have been studied in cIAI.(18) Although there 
are some concerns that critically ill patients were often 
excluded from these studies, it can be assumed that new 
antibiotics or antibiotic combinations such as ceftolozane/
tazobactam, ceftazidime/avibactam, and eravacycline can be 
successfully used in ICU patients with cIAI(19-21) (Table 2). 
The cephalosporin-based drugs need to be combined with 
metronidazole to adequately cover the anaerobic pathogens. 
Given the number of new drugs coming to the market, 
these need to be used only in patients with a high risk of 
MDR involvement or in directed therapy.(12,22)
Table 1 - Conditions for which therapeutic antimicrobials (> 24 hours) are not 
recommended, assuming that the source has been adequately controlled*
Traumatic or iatrogenic enteric perforations operated on within 12 hours
Gastroduodenal perforations operated on within 24 hours
Acute or gangrenous appendicitis without perforation
Acute or gangrenous cholecystitis without perforation
Transmural bowel necrosis without perforation, established peritonitis, or 
abscess
* Source: Based on: Mazuski JE, Tessier JM, May AK, Sawyer RG, Nadler EP, Rosengart 
MR, et al. The Surgical Infection Society Revised Guidelines on the Management of 
Intra-Abdominal Infection. Surg Infect (Larchmt). 2017;18(1):1-76.(14)
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Table 2 - Recently introduced antibiotics for complicated intra-abdominal infections and their recommended dosings
Antibiotic Antibiotic class Dose
Dosing 
frequency
Oral formulation 
available
Antimicrobial spectrum 
highlights
Remarks
Ceftolozane/tazobactam Cephalosporin + 
betalactamase 
inhibitor
1,000mg/500mg 3 times/day No Selected ESBL-producing 
Enterobacteraceae and MDR 
Pseudomonas aeruginosa, 
but not KPC
Combined with metronidazole 
for anaerobe coverage
Ceftazidime/avibactam Cephalosporin + 
betalactamase 
inhibitor
2,000mg/500mg 3 times/day No Selected ESBL-producing 
Enterobacteraceae and CRE, 
including KPC
Combined with metronidazole 
for anaerobe coverage
Clinical cure rate in a phase 3 
study was lower in patients 
with renal impairment
Eravacycline Fluorocycline 1mg/kg 2 times/day Yes MRSA, VRE, ESBL 
Enterobacteraceae and 
CRE, but not Pseudomonas 
aeruginosa
ESBL - extended spectrum beta-lactamase; MDR - multidrug resistance; KPC - Klebsiella Pneumoniae Carbapenemase; CRE - carbapenem-resistant Enterobacteraceae; MRSA - methicillin 
resistant Staphylococcus aureus; VRE - vancomycin-resistant enterococci.
Intra-abdominal candidiasis is a severe infection 
for which adequate early therapy is important, but 
antifungal prophylaxis for all patients with peritonitis 
does not appear to be beneficial
Fungal involvement in cIAI is common, particularly 
in nosocomial infections and in patients who have 
been exposed to antibiotic therapy previously.(23) Intra-
abdominal candidiasis has been linked with a high 
mortality, and its delayed administration is a risk factor 
for mortality (among other factors, such as the severity of 
illness).(24,25) Although regional variation may be present, 
Candida albicans is still the most commonly found 
pathogen.(25,26) For other infections, source control is a 
critical element in intra-abdominal candidiasis,(26) and 
when it is absent, adequate antifungal therapy has no 
relevant impact.
Intra-abdominal candidiasis or suspicion thereof is 
an important trigger for starting antifungal therapy in 
critically ill surgical patients. Many attempts to identify 
patients at risk of intra-abdominal candidiasis have been 
made in the past. Frequently used tools to predict the 
involvement of candida in ICU infections include the 
Colonization Index,(27) Candida score,(28,29) and Clinical 
Prediction Rule. Although these tools performed well in 
their original patient cohorts, their external validity seems 
to be limited, and their usefulness in clinical practice 
seems to be minimal.(30) For the prediction of candida 
involvement in abdominal infections, Dupont et al. 
developed a score that includes the length of stay before 
surgery, preoperative cardiovascular failure, generalized 
peritonitis, and upper gastrointestinal tract perforation as 
the relevant risk factors.(31) The usefulness of this model 
needs to be confirmed.
In recent years, more studies trying to identify the role 
of antifungal therapy have been performed. A large RCT 
comparing micafungin with placebo in patients requiring 
surgery and who were admitted to the ICU could not 
demonstrate any advantage of antifungal treatment in this 
setting, albeit that the antifungal therapy may have been 
administered too late to be effective.(32)
Currently, antifungal prophylaxis can be considered 
in patients with anastomotic leakage after abdominal 
surgery based on smaller (and older) studies.(33) When the 
presence of Candida spp. is confirmed, adequate therapy 
is imperative, and an echinocandin is the preferred choice 
for critically ill patients.(34) When possible, de-escalation 
to azoles can be considered in patients who are clinically 
improving.
Source control is a pivotal component of 
complicated intra-abdominal infections treatment
In patients with sepsis and septic shock, antibiotic 
therapy has been studied intensively and is consistently 
considered as being critical in the management of severe 
infections.(35) Although antibiotics are indeed essential, 
source control is at least as important as antibiotics and 
is highly relevant in patients with abdominal infections. 
However, it has been studied quite poorly, is hard to 
quantify, and requires the help of other specialties, such 
as surgery and interventional radiology. Source control 
focuses on the elimination of a septic focus and the control 
of ongoing contamination, and in the context of a cIAI, it 
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typically requires a surgical intervention or percutaneous 
drainage (PCD). A lack of source control is a particular 
problem and inevitably contributes to prolonged antibiotic 
therapy, the selection of resistant pathogens and tertiary 
peritonitis. Recent data show that source control timing 
is equally important, and in critically ill patients, Bloos et 
al. found that a delay beyond 6 hours was associated with 
a 2.3-fold increase in mortality. In fact, source control was 
the only modifiable risk factor present.(36) Percutaneous 
drainage is now increasingly used and avoids the risk of 
additional injury during a surgical intervention, although 
not all patients or infections are suited for treatment by 
PCD.(37) If there is ongoing contamination, multiple 
abscesses, thick necrosis or diffuse peritonitis, PCD 
may be of limited value. Imaging plays a critical role 
here and will help to appropriately select patients for 
either intervention. There are multiple obstacles to early 
source control, including a lack of clinical symptoms, 
concomitant infections, the perceived need for more 
investigations and availability of radiology, including that 
of ultrasound.(35) Institutional issues, such as problematic 
access to the operating theater, may also be present.
Less is more in antibiotic therapy when it comes to 
duration of therapy
The duration of antibiotic therapy is generally not one 
of the priorities in managing patients with cIAI. In most 
reports, the therapy continues for 10 - 14 days, with typically 
longer courses in nosocomial infections. Uncertainty 
in source control and the inappropriate interpretation 
of abdominal drain cultures certainly contribute to this 
phenomenon. However, it has been demonstrated that 
continued antibiotic therapy does not prevent treatment 
failure in patients with cIAI,(38) and a recent randomized 
controlled trial (RCT) from France found similar 
outcomes in patients with postoperative peritonitis who 
were treated for 8 days or 15 days (Montravers P, personal 
communication). In 2015, a multicenter RCT from 
the USA (the STOP-IT study) found that patients with 
peritonitis and an adequate source control can be treated 
with 4 days of antibiotic therapy. This was a well-designed 
study, although it should be mentioned that most of the 
patients were not critically ill, and extrapolating data to 
the ICU should be done cautiously.(39) Subgroup analyses 
on patients with sepsis did not find any advantage of 
prolonging therapy beyond 4 days, but the numbers 
were small, and the study was not powered to detect any 
effects on the major endpoints.(40) The updated guidelines 
from the Surgical Infection Society recommend limiting 
antimicrobials to 96 hours in patients who have had 
adequate source control and limiting it to 5-7 days in 
patients for whom a definitive source control procedure 
was not performed.(14) In a subgroup of patients with cIAI 
included in the SAPS study, procalcitonin (PCT)-guided 
antibiotic duration was not different from the standard 
therapy.(41) Apparently, cIAI are different from other 
infections when it comes to the role of PCT in guiding 
antibiotic therapy.
Temporary abdominal closure is increasingly used in 
the context of peritonitis
In recent years, there has been an increase in the 
use of open abdomen therapy (OAT), mainly in the 
management of trauma patients to prevent or treat 
abdominal compartment syndrome.(42) However, the 
concepts of damage control in the trauma setting are 
now also being applied in patients with severe peritonitis. 
This includes a rapid intervention aimed at removing the 
focus of infection and associated necrosis, temporarily 
controlling ongoing contamination (e.g., using staplers to 
seal perforations), and planning for secondary repair after 
restoration of the physiology of the patient. As in trauma, 
these patients are at increased risk for intra-abdominal 
hypertension due to an increased intra-abdominal volume 
because of ileus obstruction, ischemia/reperfusion injury, 
and accumulation of resuscitation fluids and due to 
decreased abdominal compliance because of pain and the 
laparotomy incision. Hence, OAT is increasingly applied 
as a preventive strategy. When an OAT approach is used, 
negative pressure wound therapy with fascial traction is 
reportedly the best solution in terms of complications and 
closure rates.(43) Techniques such as the Bogota bag, mesh 
techniques and Zipper are associated with a significant risk 
for fistula and tend to have low abdominal closure rates.
Studies have also been investigating the potential 
effect of negative pressure wound therapy (NPWT) on 
removing inflammatory cytokines from the abdominal 
cavity. Indeed, in an animal model, systemic inflammation 
was attenuated by removing the abdominal fluid using 
NPWT, which had a beneficial effect on organ function.(44) 
In the only human study so far, Kirkpatrick et al. observed 
a reduced mortality in NPWT but could not demonstrate 
any effect on systemic inflammation,(45) and the exact role 
of NPWT needs to be elucidated.
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Conclusion
Managing complicated intra-abdominal infections 
in the intensive care unit remains a challenging issue, 
with an increase in multidrug resistance infections being 
the most imminent threat to patients with peritonitis, 
which further stresses the role of rational antibiotic use 
for both older and newly introduced antibiotics, such 
as ceftolozane/tazobactam, ceftazidime/avibactam and 
eravacycline, which should be used preferably in patients 
with documented multidrug resistance infections or in 
those who are at an increased risk of multidrug resistance 
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